title: Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.
abstract: To clarify the social disadvantages associated with myasthenia gravis (MG) and examine associations with its disease and treatment.
  
  
  
  Cross-sectional study.
  
  
  
  We evaluated 917 consecutive cases of established MG seen at 13 neurological centres in Japan over a short duration.
  
  
  
  All patients completed a questionnaire on social disadvantages resulting from MG and its treatment and a 15-item MG-specific quality of life scale at study entry. Clinical severity at the worst condition was graded according to the MG Foundation of America classification, and that at the current condition was determined according to the quantitative MG score and MG composite. Maximum dose and duration of dose ≥20 mg/day of oral prednisolone during the disease course were obtained from the patients' medical records. Achievement of the treatment target (minimal manifestation status with prednisolone at ≤5 mg/day) was determined at 1, 2 and 4 years after starting treatment and at study entry.
  
  
  
  We found that 27.2% of the patients had experienced unemployment, 4.1% had been unwillingly transferred and 35.9% had experienced a decrease in income, 47.1% of whom reported that the decrease was ≥50% of their previous total income. In addition, 49.0% of the patients reported feeling reduced social positivity. Factors promoting social disadvantages were severity of illness, dose and duration of prednisolone, long-term treatment, and a depressive state and change in appearance after treatment with oral steroids. Early achievement of the treatment target was a major inhibiting factor.
  
  
  
  Patients with MG often experience unemployment, unwilling job transfers and a decrease in income. In addition, many patients report feeling reduced social positivity. To inhibit the social disadvantages associated with MG and its treatment, greater focus needs to be placed on helping patients with MG resume a normal lifestyle as soon as possible by achieving the treatment target.
authors.affiliation: Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Nagane
authors.affiliation: Department of Neurological Therapeutics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Murai
authors.affiliation: Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan.
authors.forename: Tomihiro
authors.initials: T
authors.lastname: Imai
authors.affiliation: Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yamamoto
authors.affiliation: Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan.
authors.forename: Emiko
authors.initials: E
authors.lastname: Tsuda
authors.affiliation: Department of Neurology, Hokkaido Medical Center, Sapporo, Japan.
authors.forename: Naoya
authors.initials: N
authors.lastname: Minami
authors.affiliation: Department of Neurology, Sendai Medical Center, Sendai, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Suzuki
authors.affiliation: Department of Neurology, Chiba University School of Medicine, Chiba, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kanai
authors.affiliation: Department of Neurology, Chiba University School of Medicine, Chiba, Japan.
authors.forename: Akiyuki
authors.initials: A
authors.lastname: Uzawa
authors.affiliation: Chiba Neurology Clinic, Chiba, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Kawaguchi
authors.affiliation: Department of Neurology, Tokyo Medical University, Tokyo, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Masuda
authors.affiliation: Department of Neurology, Toho University Oh-hashi Medical Center, Tokyo, Japan.
authors.forename: Shingo
authors.initials: S
authors.lastname: Konno
authors.affiliation: Department of Neurology, Kinki University School of Medicine, Osaka, Japan.
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.affiliation: Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Aoki
authors.affiliation: Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
authors.forename: Kimiaki
authors.initials: K
authors.lastname: Utsugisawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D003863:Depression / Q000453:epidemiology*; D005260:Female; D006801:Humans; D007182:Income / Q000706:statistics & numerical data*; D007564:Japan; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000523:psychology*; D011239:Prednisolone / Q000008:administration & dosage; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D012720:Severity of Illness Index; D012944:Social Support; D011795:Surveys and Questionnaires; D014478:Unemployment / Q000706:statistics & numerical data*; D055815:Young Adult
chemical_list: D011239:Prednisolone
keywords: MENTAL HEALTH; SOCIAL MEDICINE